Coming together for the first time, O=Mega23, the largest clinical conference and trade show for optometry in the Southern Hemisphere, and the fourth World Congress of Optometry will firmly plant Australian optometry on the world stage next year, say organisers.
Twelve years in the making, Vision Bus Aotearoa was officially launched on 10 June at a University of Auckland ceremony attended by Governor-General Dame Cindy Kiro.
A research project proposing a novel non-invasive method to measure intracranial pressure (ICP), in a safe and timely manner, has been awarded one of 17 Explorer Grants by New Zealand’s Health Research Council (HRC).
Titled ‘A Secure Future’, the 2022 Budget included $191m over two years for Pharmac and $168m for the Māori Health Authority, as part of a record-breaking $13.2bn healthcare investment.
Ashvattha Therapeutics’ phase 1 trial of patient-administered subcutaneous doses of its anti-VEGF therapy have shown it to be safe and well tolerated in healthy subjects. “We are advancing this first-in-class therapy to enable patients the convenience of self-administration with an autoinjector up t
Australian researchers have found retinal pigment epithelial (RPE) cells appear to be particularly susceptible to harbouring Ebola and other viruses. Uveitis occurs in up to one-third of Ebola
Researchers from the National Eye Institute (NEI) have identified a novel genetic macular dystrophy, which is yet to be named. “Affected individuals had scotomas and changes in their maculas
Clinical trial results for Tepezza, the only thyroid eye disease (TED) treatment approved by the US Food and Drug Administration (FDA), have associated the drug with hyperglycaemia in 10% of
Pilot evaluation for an image-based eyelid lesion management service
A West Australian (WA) research team is testing the eyes of 500 patients to investigate possible links between sleep apnoea and the development of glaucoma.
Alcon has signed a US$60 million agreement to acquire Kala Pharmaceuticals’ loteprednol etabonate products Eysuvis 0.25% for dry-eye disease (DED) and Inveltys 1%, for post-operative inflammation and pain.
Researchers at the Auckland Bioengineering Institute at Auckland University have received $150,000 from the Health Research Council for a project aiming to transform the understanding, predictability and, ultimately, prevention of the long-term impact of traumatic brain injury (TBI).